A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
| Status: | Withdrawn |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 35 - Any |
| Updated: | 6/30/2018 |
| Start Date: | June 2018 |
| End Date: | January 2019 |
Pharmacokinetics of Lanabecestat (LY3314814) in Subjects With Impaired Renal Function
The purpose of the study is to determine whether lanabecestat can be safely prescribed in
participants with kidney impairment without a dose adjustment.
Participants will be on study for up to 6 weeks; this includes a 2-week screening and a
follow-up about 10 days after final drug administration.
participants with kidney impairment without a dose adjustment.
Participants will be on study for up to 6 weeks; this includes a 2-week screening and a
follow-up about 10 days after final drug administration.
Inclusion Criteria:
- Have a body mass index (BMI) of 19 to 40 kilograms per meter square (kg/m²)
Exclusion Criteria:
- Have a history of or current significant ophthalmic disease, particularly any eye
problem involving the retina
- Have moderate or severe vitiligo or any other clinically significant disorder of skin
or hair pigmentation
- Have acute unstable neuropsychiatric disease
- Have active or uncontrolled neurologic disease, or clinically significant head injury
We found this trial at
3
sites
5055 South Orange Ave Orlando FL 32909
Orlando, Florida 32806
Orlando, Florida 32806
407-240-7878
Principal Investigator: T C Marbury
Click here to add this to my saved trials
Miami, Florida 33014
Principal Investigator: K C Lasseter
Phone: 305-817-2900
Click here to add this to my saved trials
Tustin, California
Principal Investigator: J M Neutal
Phone: 714-550-9990
Click here to add this to my saved trials